Departments of1Neurological Surgery and.
2Radiation Oncology, University of California, San Francisco, California.
J Neurosurg. 2023 Aug 4;140(2):404-411. doi: 10.3171/2023.6.JNS222629. Print 2024 Feb 1.
The purpose of this study was to identify rates of and risk factors for local tumor progression in patients who had undergone surgery or radiosurgery for the management of cerebellar hemangioblastoma and to describe treatments pursued following tumor progression.
The authors conducted a retrospective single-center review of patients who had undergone treatment of a cerebellar hemangioblastoma with either surgery or stereotactic radiosurgery (SRS) between 1996 and 2019. Univariate and multivariate regression analyses were performed to examine factors associated with local tumor control.
One hundred nine patients met the study inclusion criteria. Overall, these patients had a total of 577 hemangioblastomas, 229 of which were located in the cerebellum. The surgical and SRS cohorts consisted of 106 and 123 cerebellar hemangioblastomas, respectively. For patients undergoing surgery, tumors were treated with subtotal resection and gross-total resection in 5.7% and 94.3% of cases, respectively. For patients receiving SRS, the mean target volume was 0.71 cm3 and the mean margin dose was 18.0 Gy. Five-year freedom from lesion progression for the surgical and SRS groups was 99% and 82%, respectively. The surgical and SRS cohorts contained 32% versus 97% von Hippel-Lindau tumors, 78% versus 7% cystic hemangioblastomas, and 12.8- versus 0.56-cm3 mean tumor volumes, respectively. On multivariate analysis, factors associated with local tumor progression in the SRS group included older patient age (HR 1.06, 95% CI 1.03-1.09, p < 0.001) and a cystic component (HR 9.0, 95% CI 2.03-32.0, p = 0.001). Repeat SRS as salvage therapy was used more often for smaller tumor recurrences, and no tumor recurrences of < 1.0 cm3 required additional salvage surgery following repeat SRS.
Both surgery and SRS achieve high rates of local control of hemangioblastomas. Age and cystic features are associated with local progression after SRS treatment for cerebellar hemangioblastomas. In cases of local tumor recurrence, salvage surgery and repeat SRS are valid forms of treatment to achieve local tumor control, although resection may be preferable for larger recurrences.
本研究旨在确定小脑血管瘤患者行手术或放射外科治疗后局部肿瘤进展的发生率和风险因素,并描述肿瘤进展后的治疗方法。
作者对 1996 年至 2019 年间行手术或立体定向放射外科(SRS)治疗小脑血管瘤的患者进行了回顾性单中心研究。采用单因素和多因素回归分析来研究与局部肿瘤控制相关的因素。
109 例患者符合研究纳入标准。这些患者共 577 个血管瘤,其中 229 个位于小脑。手术组和 SRS 组分别有 106 个和 123 个小脑血管瘤。行手术治疗的患者中,肿瘤分别采用次全切除和大体全切除,占比分别为 5.7%和 94.3%。行 SRS 治疗的患者,靶区平均体积为 0.71cm³,边缘剂量平均为 18.0Gy。手术组和 SRS 组的 5 年无病变进展率分别为 99%和 82%。手术组和 SRS 组分别有 32%和 97%的患者患有 von Hippel-Lindau 肿瘤,78%和 7%的患者患有囊性血管瘤,肿瘤平均体积分别为 12.8cm³和 0.56cm³。多因素分析显示,SRS 组局部肿瘤进展的相关因素包括患者年龄较大(HR 1.06,95%CI 1.03-1.09,p<0.001)和囊性成分(HR 9.0,95%CI 2.03-32.0,p=0.001)。对于较小的肿瘤复发,更常采用重复 SRS 作为挽救性治疗,而对于<1.0cm³的肿瘤复发,在重复 SRS 后无需进行额外的挽救性手术。
手术和 SRS 均能实现较高的血管瘤局部控制率。年龄和囊性特征与 SRS 治疗小脑血管瘤后局部进展相关。对于局部肿瘤复发,挽救性手术和重复 SRS 是实现局部肿瘤控制的有效治疗方法,尽管对于较大的复发,切除可能更为理想。